SIFI, la più importante azienda oftalmica italiana, opera nel settore della cura dell’occhio dal 1935.
La sua missione è quella di fornire agli oftalmologi e ai loro pazienti una vasta gamma di soluzioni terapeutiche alle patologie oculari più diffuse, producendo e commercializzando innovativi farmaci e dispositivi medici.
Azienda con un business model integrato, dalla ricerca e sviluppo, alla produzione e commercializzazione sia in ambito farmaceutico che biomedicale, sostiene il proprio vantaggio competitivo coniugando la ricerca e sviluppo interna, che negli ultimi anni ha generato oltre 60 brevetti a livello mondiale, con una consolidata rete internazionale di alleanze per lo sviluppo di nuovi prodotti e per la commercializzazione all’estero del suo ampio portafoglio.
SIFI completa la sua offerta con nutraceutici, prodotti per l’igiene oculare e strumenti diagnostici, frutto del proprio know-how specifico nel settore.
La sua storia di quasi ottant’anni è caratterizzata dal perseguimento dell’eccellenza e dall’elevato livello di servizio alla classe medica oftalmica, prevalentemente in Italia.
Attualmente il Gruppo SIFI conta più di 360 dipendenti, di cui oltre 20 impegnati nell'area Ricerca e Sviluppo, e raggiunge un fatturato di circa 65 milioni di euro, investendo circa il 10% dei ricavi in R&D.
Il Gruppo è strutturato in due aree di business – Pharma e Medtech – ed è presente in oltre 15 paesi del mondo, con filiali commerciali in Messico e Romania.
SIFI, the leading Italian ophthalmic company, has been focused on Eye Care since its foundation in 1935.
Our mission is to provide ophthalmologists and their patients with a wide range of therapeutic solutions to treat the most common eye diseases, by manufacturing and marketing innovative pharmaceuticals and medical devices.
SIFI features an integrated business model, from research & development to manufacturing and commercialization both in the pharmaceutical and biomedical sectors. SIFI develops its competitive advantage through a combination of internal R&D, which has led to more than 60 patents in the last few years, and a strong international network of alliances to develop new products and to market its wide product portfolio overseas.
Our offering is completed with ophthalmic nutraceuticals, cosmetics and diagnostic instruments, that leverage on our specialty know-how.
SIFI’s 80-years history is distinguished with the pursuit of excellence and the highest level of educational service to the ophthalmic community, most notably in Italy.
Currently the SIFI Group employs around 360 people – more than 20 in R&D - and has a turnover of about € 65 million. Each year SIFI invests approximately 10% of sales in R&D.
The Group is organized into two business areas – Pharma and Medtech – and its products are sold in more than 15 countries worldwide, with commercial subsidiaries in Mexico and Romania.
La sua missione è quella di fornire agli oftalmologi e ai loro pazienti una vasta gamma di soluzioni terapeutiche alle patologie oculari più diffuse, producendo e commercializzando innovativi farmaci e dispositivi medici.
Azienda con un business model integrato, dalla ricerca e sviluppo, alla produzione e commercializzazione sia in ambito farmaceutico che biomedicale, sostiene il proprio vantaggio competitivo coniugando la ricerca e sviluppo interna, che negli ultimi anni ha generato oltre 60 brevetti a livello mondiale, con una consolidata rete internazionale di alleanze per lo sviluppo di nuovi prodotti e per la commercializzazione all’estero del suo ampio portafoglio.
SIFI completa la sua offerta con nutraceutici, prodotti per l’igiene oculare e strumenti diagnostici, frutto del proprio know-how specifico nel settore.
La sua storia di quasi ottant’anni è caratterizzata dal perseguimento dell’eccellenza e dall’elevato livello di servizio alla classe medica oftalmica, prevalentemente in Italia.
Attualmente il Gruppo SIFI conta più di 360 dipendenti, di cui oltre 20 impegnati nell'area Ricerca e Sviluppo, e raggiunge un fatturato di circa 65 milioni di euro, investendo circa il 10% dei ricavi in R&D.
Il Gruppo è strutturato in due aree di business – Pharma e Medtech – ed è presente in oltre 15 paesi del mondo, con filiali commerciali in Messico e Romania.
SIFI, the leading Italian ophthalmic company, has been focused on Eye Care since its foundation in 1935.
Our mission is to provide ophthalmologists and their patients with a wide range of therapeutic solutions to treat the most common eye diseases, by manufacturing and marketing innovative pharmaceuticals and medical devices.
SIFI features an integrated business model, from research & development to manufacturing and commercialization both in the pharmaceutical and biomedical sectors. SIFI develops its competitive advantage through a combination of internal R&D, which has led to more than 60 patents in the last few years, and a strong international network of alliances to develop new products and to market its wide product portfolio overseas.
Our offering is completed with ophthalmic nutraceuticals, cosmetics and diagnostic instruments, that leverage on our specialty know-how.
SIFI’s 80-years history is distinguished with the pursuit of excellence and the highest level of educational service to the ophthalmic community, most notably in Italy.
Currently the SIFI Group employs around 360 people – more than 20 in R&D - and has a turnover of about € 65 million. Each year SIFI invests approximately 10% of sales in R&D.
The Group is organized into two business areas – Pharma and Medtech – and its products are sold in more than 15 countries worldwide, with commercial subsidiaries in Mexico and Romania.
Location: Italy, Sicily, Aci Sant'Antonio
Employees: 201-500
Phone: +39 095 792 2111
Founded date: 1935
Investors 1
Date | Name | Website |
- | 21 Invest | 21invest.c... |
Mentions in press and media 6
Date | Title | Description |
26.08.2024 | SIFI Receives European Commission Approval for AKANTIOR® | AKANTIOR® (polihexanide) is the first and only approved drug for the treatment of acanthamoeba keratitis CATANIA, Italy, Aug. 26, 2024 /PRNewswire/ -- SIFI, a leading international ophthalmic company, today announced the European Commission... |
31.05.2024 | SIFI receives positive CHMP opinion for AKANTIOR® (polihexanide 0.08%) in acanthamoeba keratitis | ACI SANT'ANTONIO, Italy, May 31, 2024 /PRNewswire/ -- SIFI announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of AKANTIOR® (po... |
08.09.2023 | SIFI TO PRESENT NEW SCIENTIFIC DATA DURING THE 41ST CONGRESS OF THE EUROPEAN SOCIETY OF CATARACT AND REFRACTIVE SURGEONS | CATANIA, Italy, Sept. 8, 2023 /PRNewswire/ -- SIFI, a leading international ophthalmic company, is pleased to announce the presentation of new scientific data on its products during the upcoming Congress of The European Society of Cataract ... |
15.09.2022 | SIFI TO PRESENT NEW SCIENTIFIC DATA AND LAUNCH A NEW INTRAOCULAR LENS DURING THE 40TH CONGRESS OF THE EUROPEAN SOCIETY OF CATARACT AND REFRACTIVE SURGEONS | CATANIA, Italy, Sept. 15, 2022 /PRNewswire/ -- SIFI, a leading international ophthalmic company, announces 3 scientific presentations on its latest innovations during the upcoming Congress of The European Society of Cataract and Refractive ... |
14.03.2022 | SIFI Announces the Grant of a Second FDA Orphan Drug Designation for Polihexanide in Fungal Keratitis | This follows the previously-granted ODD for polihexanide in Acanthamoeba Keratitis by the FDA and EMA. An estimated 15,660 patients with fungal keratitis are diagnosed annually in the US. CATANIA, Italy, March 14, 2022 /PRNewswire/ -- SIFI ... |
01.02.2021 | SIFI Announces the Publication of its Phase I Study on Polihexanide in the British Journal of Ophthalmology USA - English France - Français Deutschland - Deutsch España - español |